Equities analysts predict that Liquidia Technologies Inc (NASDAQ:LQDA) will report $1.03 million in sales for the current fiscal quarter, Zacks Investment Research reports. Two analysts have made estimates for Liquidia Technologies’ earnings, with estimates ranging from $1.00 million to $1.06 million. The company is expected to issue its next earnings report on Wednesday, January 30th.
According to Zacks, analysts expect that Liquidia Technologies will report full-year sales of $4.10 million for the current year, with estimates ranging from $4.09 million to $4.10 million. For the next financial year, analysts forecast that the company will report sales of $3.07 million, with estimates ranging from $2.93 million to $3.20 million. Zacks’ sales calculations are an average based on a survey of sell-side analysts that that provide coverage for Liquidia Technologies.
Liquidia Technologies (NASDAQ:LQDA) last issued its quarterly earnings results on Wednesday, October 31st. The company reported ($0.83) earnings per share for the quarter, missing the consensus estimate of ($0.57) by ($0.26). The firm had revenue of $0.17 million during the quarter, compared to analysts’ expectations of $1.03 million.
A number of analysts have recently weighed in on LQDA shares. Jefferies Financial Group started coverage on Liquidia Technologies in a research report on Monday, August 20th. They issued a “buy” rating and a $22.00 price objective for the company. Wedbush started coverage on Liquidia Technologies in a research report on Tuesday, September 4th. They issued an “outperform” rating and a $26.00 price objective for the company. Needham & Company LLC set a $32.00 price objective on Liquidia Technologies and gave the stock a “buy” rating in a research report on Wednesday. Finally, Cowen set a $40.00 price objective on Liquidia Technologies and gave the stock a “buy” rating in a research report on Wednesday.
Shares of NASDAQ LQDA opened at $19.60 on Friday. Liquidia Technologies has a 12-month low of $10.52 and a 12-month high of $38.46.
About Liquidia Technologies
Liquidia Technologies, Inc is a late-stage clinical biopharmaceutical company focused on the development and commercialization of human therapeutics using its proprietary PRINT technology to transform the lives of patients. PRINT technology is a particle engineering platform that enables precise production of uniform drug particles designed to improve the safety, efficacy and performance of a wide range of therapies.
Featured Story: Balance Sheet
Get a free copy of the Zacks research report on Liquidia Technologies (LQDA)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Liquidia Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Liquidia Technologies and related companies with MarketBeat.com's FREE daily email newsletter.